Aldolase A Accelerates Cancer Progression by Modulating mRNA Translation and Protein Biosynthesis via Noncanonical Mechanisms

Adv Sci (Weinh). 2023 Sep;10(26):e2302425. doi: 10.1002/advs.202302425. Epub 2023 Jul 11.

Abstract

Aldolase A (ALDOA), a crucial glycolytic enzyme, is often aberrantly expressed in various types of cancer. Although ALDOA has been reported to play additional roles beyond its conventional enzymatic role, its nonmetabolic function and underlying mechanism in cancer progression remain elusive. Here, it is shown that ALDOA promotes liver cancer growth and metastasis by accelerating mRNA translation independent of its catalytic activity. Mechanistically, ALDOA interacted with insulin- like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to facilitate its binding to m6 A-modified eIF4G mRNA, thereby increasing eIF4G protein levels and subsequently enhancing overall protein biosynthesis in cells. Importantly, administration of GalNAc-conjugated siRNA targeting ALDOA effectively slows the tumor growth of orthotopic xenografts. Collectively, these findings uncover a previously unappreciated nonmetabolic function of ALDOA in modulating mRNA translation and highlight the potential of specifically targeting ALDOA as a prospective therapeutic strategy in liver cancer.

Keywords: Aldolase A (ALDOA); IGF2BP1; eIF4G; hepatocellular carcinoma; insulin-like growth factor 2 mRNA-binding protein 1; mRNA translation; protein biosynthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Eukaryotic Initiation Factor-4G
  • Fructose-Bisphosphate Aldolase* / genetics
  • Humans
  • Liver Neoplasms* / genetics
  • RNA, Small Interfering / metabolism

Substances

  • Fructose-Bisphosphate Aldolase
  • Eukaryotic Initiation Factor-4G
  • RNA, Small Interfering